Status:
COMPLETED
Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will provide a direct comparison of 'continuous therapy' and 'intermittent therapy' with withdrawal and retreatment upon return of psoriasis.
Eligibility Criteria
Inclusion
- Stable, active plaque psoriasis
- Failure to respond to the following systemic therapies: Methotrexate, Cyclosporine, PUVA or Fumarate
Exclusion
- Evidence of skin conditions other than psoriasis that would interfere with evaluations of the effect of the study
- Systemic psoriasis therapy within 28 days prior
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
720 Patients enrolled
Trial Details
Trial ID
NCT00195507
Start Date
December 1 2004
End Date
February 1 2007
Last Update
February 25 2013
Active Locations (127)
Enter a location and click search to find clinical trials sorted by distance.
1
Feldkirch, Austria
2
Vienna, Austria, 1090
3
Vienna, Austria, 1160
4
Brussels, Belgium, B-1070